Browse CDH5

Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction Cell membrane Single-pass type I membrane protein Note=Found at cell-cell boundaries and probably at cell-matrix boundaries. KRIT1 and CDH5 reciprocally regulate their localization to endothelial cell-cell junctions.
Domain PF00028 Cadherin domain
PF01049 Cadherin cytoplasmic region
Function

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction.

> Gene Ontology
 
Biological Process GO:0001885 endothelial cell development
GO:0001955 blood vessel maturation
GO:0002064 epithelial cell development
GO:0003158 endothelium development
GO:0007043 cell-cell junction assembly
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007163 establishment or maintenance of cell polarity
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0010720 positive regulation of cell development
GO:0021700 developmental maturation
GO:0030010 establishment of cell polarity
GO:0030856 regulation of epithelial cell differentiation
GO:0030858 positive regulation of epithelial cell differentiation
GO:0032878 regulation of establishment or maintenance of cell polarity
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0034332 adherens junction organization
GO:0045216 cell-cell junction organization
GO:0045446 endothelial cell differentiation
GO:0045601 regulation of endothelial cell differentiation
GO:0045603 positive regulation of endothelial cell differentiation
GO:0061028 establishment of endothelial barrier
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071695 anatomical structure maturation
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1901550 regulation of endothelial cell development
GO:1901552 positive regulation of endothelial cell development
GO:1903140 regulation of establishment of endothelial barrier
GO:1903142 positive regulation of establishment of endothelial barrier
GO:2000114 regulation of establishment of cell polarity
Molecular Function GO:0008013 beta-catenin binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0044325 ion channel binding
Cellular Component GO:0005923 bicellular tight junction
GO:0009897 external side of plasma membrane
GO:0043296 apical junction complex
GO:0070160 occluding junction
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04670 Leukocyte transendothelial migration
Reactome R-HSA-418990: Adherens junctions interactions
R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-162582: Signal Transduction
R-HSA-194138: Signaling by VEGF
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218920: VEGFR2 mediated vascular permeability
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDH5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CDH5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28655790MelanomaPromote immunityWe developed an oligonucleotide-based inhibitor (CD5-2), which disrupted the interaction of VE-cadherin with its regulator miR-27a, resulting in increased VE-cadherin expression. Administration of CD5-2 in tumor-bearing mice enhanced expression of VE-cadherin in tumor endothelium, activating TIE-2 and tight junction pathways and normalizing vessel structure and function. Our work establishes a role for VE-cadherin in T-cell infiltration in tumors and offers a preclinical proof of concept for CD5-2 as a therapeutic modifier of cancer immunotherapy via effects on the tumor vasculature.
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDH5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDH5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4690.141
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5260.716
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4210.672
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2620.546
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9070.612
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5520.808
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4830.287
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6620.621
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2570.866
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1520.496
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.4340.292
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.20.091
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDH5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDH5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDH5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDH5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDH5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDH5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDH5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDH5
Namecadherin 5, type 2 (vascular endothelium)
Aliases 7B4; CD144; VE-cadherin; cadherin 5, type 2, VE-cadherin (vascular epithelium); 7B4 antigen; cd144 antigen; ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDH5 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CDH5.
ID Name Drug Type Targets #Targets
DB00480LenalidomideSmall MoleculeCDH5, CRBN, PTGS2, TNFSF114
DB05685FX06BiotechCDH51